InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Says Recent Acquisition to Help Capitalize on ‘Tremendous’ Potential in iGaming Market
October 9, 2024
180 Life Sciences (NASDAQ: ATNF) today announced that it can now fully focus on developing its new iGaming business after officially regaining compliance with Nasdaq Listing Rule 5550(b)(1) on minimum stockholders’ equity. The company announced earlier this month that it will be strategically shifting towards the growing global iGaming sector as it seeks to leverage […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Provides Update on Strategic Corporate Initiatives
October 3, 2024
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has released an update on several key initiatives, including announcing the acquisition of an advanced Gaming Technology Platform, positive progress on its Legacy CBD formulation and a strengthened balance sheet. According to the update, the company is shifting its focus as it enters the global iGaming […]
Octane Medical Innovation Forum to be held on Oct 8-9 in Irvine, California
September 18, 2024
IRVINE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) — via InvestorWire — Octane, an innovative organization building the SoCal of Tomorrow by connecting people, resources and capital to fuel technology growth in Southern California, is pleased to announce that the Octane Medical Innovation Forum 2024 (“OMIF”) will be held on October 8-9, 2024 at the Irvine Marriott, 18000 Von […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Appoints Omar Jimenez as Chief Financial Officer
September 13, 2024
180 Life Sciences (NASDAQ: ATNF) announced on Thursday its appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Jimenez, a current director of the Company, will leverage his extensive financial management experience to steer the Company’s growth and innovation in the pharmaceutical and biotechnology sectors. With a background that includes […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Reports on Human Clinical Trial Evaluating Solid Formulation of CBD with Enhanced Oral Uptake
July 30, 2024
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, is reporting on its clinical pharmacology study designed to evaluate the uptake of cannabidiol (“CBD”) in a solid formulation that can be delivered as a pill. According to the report, the clinical trial, which was performed with Professor Avi Domb of the Hebrew University, School of […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Granted Additional Extension to Regain Compliance with Continued Nasdaq Listing Requirements
July 23, 2024
180 Life Sciences (NASDAQ: ATNF) today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “hearings panel”) of the Nasdaq Stock Market LLC that it has granted the company’s request for additional time to achieve compliance with Nasdaq’s continued listing rules and demonstrate long-term compliance with the Equity Rule. Specifically, the hearings […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Granted Extension to Regain Compliance with Nasdaq Listing Requirements
July 2, 2024
180 Life Sciences (NASDAQ: ATNF) today announced its receipt of notice from the Nasdaq Listing Qualifications Panel of the Nasdaq Stock Market LLC that the panel has determined to grant the company’s request to continue its listing on the Nasdaq Stock Market. The continued listing is subject to the company meeting certain conditions, including filing […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Regains Compliance with Nasdaq Minimum Bid Price Requirement
March 14, 2024
180 Life Sciences (NASDAQ: ATNF) today announced that it received a letter on March 13, 2024, from the Nasdaq Stock Market LLC indicating that the company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”). As detailed in the […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Plans 1-for-19 Reverse Stock Split to Regain NASDAQ Compliance
February 26, 2024
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, will conduct a reverse stock split of its outstanding shares of common stock. The ratio of the reverse stock split, which is slated to go into effect on Feb. 28 with market open, will be 1-for-19. According to the announcement, the reverse stock split, which was […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Engagement of Alliance Global Partners
December 4, 2023
180 Life Sciences (NASDAQ: ATNF) today announced it has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value. According to the announcement, potential alternatives that may be explored or evaluated by 180 Life Sciences as part of this process include, but are not limited to, an acquisition, […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Officials, Board to Review of Strategic Alternatives
November 28, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, and its board of directors has initiated a process to evaluate potential strategic alternatives. The goal of the process is to identify ways to unlock and maximize shareholder value. According to the announcement, company officials are working with financial and legal advisors as they consider a […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on $3M Public Offering
August 15, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has closed on its previously announced public offering. The offering was comprised of 4,615,385 shares of the company’s common stock (or common stock equivalents in lieu thereof) as well as warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Public Offering Pricing, Offering Could Reach $3M
August 10, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, announced the pricing of its current public offering. The offering consists of up to 4,615,385 shares of the company’s common stock and warrants for purchase at $0.65 per share. According to the announcement, the warrants, which will expire on Oct. 10, 2028, will be immediately exercisable […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Enters Agreement for Strategic PK Study
August 7, 2023
180 Life Sciences (NASDAQ: ATNF) today announced its entry into an agreement with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, to perform a clinical pharmacology (“PK”) study of the uptake of cannabidiol (“CBD”) in a formulation that can be delivered as an oral pill. […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Update on Regulatory Approval Process for Dupuytren’s Disease Treatment
August 3, 2023
180 Life Sciences (NASDAQ: ATNF) is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain. The company today announced that it has submitted a request to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (“MHRA”) for a follow-up scientific advice meeting where […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite
July 31, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced the filing of a provisional patent describing the novel combination of cannabidiol (“CBD”), or an analog thereof, with glucagon related peptide-1 (“GLP-1”) agonists to address obesity and weight management. Co-administration of CBD, a known appetite suppressant and antiemetic, might be expected both to limit […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on $3M Registered Direct Offering, Concurrent Private Placement
April 11, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has closed on its previously announced issuance and sale of 1,570,680 shares of the company’s common stock in a registered direct offering and warrants. The shares were offered at a purchase price of $1.91 in a concurrent private placement, resulting in gross proceeds of an estimated […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $3M Registered Direct, Concurrent Private Placement
April 5, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced its entry into a definitive agreement with a health care-focused U.S. institutional investor. The agreement is for the purchase and sale of 1,570,680 shares of the company’s common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at Summer Research Conference
February 27, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, will be participating at the Gordon Research Conference, which is slated for July 9–14, 2023. The presentation, which is titled “Physiological and Disease Relevance and Underlying Molecular Properties of Collagens,” will be presented by Professor Jagdeep Nanchahal. The conference will be held at Colby-Sawyer College in […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Update on Change of Status for Anti-TNF Frozen Shoulder Trial, Receives Patent Notification
February 23, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has closed recruitment in England for its anti-TNF frozen shoulder trial. The company had been enrolling men and women with early-stage frozen shoulder to participate in the study, which was called the Anti-Freaze-F trial. The study was designed to evaluate whether an intra-articular injection of anti-TNF (Adalimumab) […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Medical Advisory Board Chair Coauthors Review of Early Stage Dupuytren’s Disease Treatment
January 25, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has announced the publication of a review written by Professor Jagdeep Nanchahal, chair of ATNF’s medical advisory board; the review was also written by a colleague of Nanchahal’s from the University of Oxford. Titled “Treatments for early stage Dupuytren’s disease: An evidence-based approach,” the article was […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Engages Kinexum for Assistance in MAA Submission
January 17, 2023
180 Life Sciences (NASDAQ: ATNF) today announced its engagement of Kinexum, a strategic advisory firm, to support the company in submitting a Marketing Authorisation Application (“MAA”) for adalimumab to treat progressive early-stage Dupuytren’s disease. According to the announcement, the MAA will be submitted to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (“MHRA” or […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Is Notified by NASDAQ Exchange of Full Compliance
January 5, 2023
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has regained full compliance with NASDAQ minimum-bid price requirements. The company received a letter from the NASDAQ Stock Market LLC providing notification of the change in status; the letter was dated Jan. 4, 2023. According to the letter, the exchange determined that the closing bid price […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Review on Molecular Basis of Dupuytren’s Disease
January 4, 2023
180 Life Sciences (NASDAQ: ATNF) today announced the publication of a review entitled “Dupuytren’s disease: a localized and accessible human fibrotic disorder” in the journal Trends in Molecular Medicine. In the article, the authors at the University of Oxford, led by Professor Jagdeep Nanchahal, chairman of the medical advisory board of 180 Life Sciences, describe […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Shareholder Letter with Corporate Update
December 29, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has released a letter to shareholders; the letter is signed by CEO James Woody. In the letter, Woody notes that the company’s priority continues to be its clinical programs, repurposing anti-tumor necrosis factor (“TNF”) drugs for the treatment of Dupuytren’s disease, frozen shoulder and post-operative delirium. […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on Registered Direct Offering for $6M
December 27, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has closed on its previously announced registered direct offering. The offering, which was with a single healthcare-focused U.S. institutional investor, was comprised of 1,714,286 shares of the company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,571,429 shares of […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Enters into Registered Direct Offering Agreement for $6M Proceeds
December 21, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has entered into a definitive agreement with a single healthcare-focused U.S. institutional investor. The agreement is for a registered direct offering to include the purchase and sale of 1,714,286 shares of the company’s common stock (or common stock equivalents in lieu thereof) and warrants to […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Status Update on MHRA Interaction
December 1, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, is sharing an update on its efforts to seek marketing authorization from Medicines and Healthcare Products Regulatory Agency (MHRA) for Anti-TNF treatment of early-stage Dupuytren’s Contracture. ATNF officials, along with representatives from the company’s regulatory consultants from the United States and the United Kingdom, met with […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Participation in Upcoming Biotech Conference
November 21, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, will be participating in A.G.P.’s Virtual Biotech Conference. The conference is scheduled for Nov. 30–Dec. 1, 2022. According to the announcement, ATNF president and CEO Dr. James Woody will present […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Adalimumab Has Promise as Treatment for Early-Stage Dupuytren’s Disease
November 15, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has announced that adalimumab, its anti-TNF treatment, has shown potential to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease. According to the announcement, researchers at Oxford Population Health’s Health Economics Research Centre and the Kennedy Institute of Rheumatology have identified the potential; adalimumab […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders
September 26, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today released a letter to stockholders from its Chief Executive Officer Dr. James Woody. In the letter, Dr. Woody discussed the company’s continued status to remain on track with clinical development plans. “Currently, we have an active clinical development program that includes phase 2a and phase […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Enrolls First Patient in Early-Stage Frozen Shoulder Trial
August 22, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, is noting a significant milestone reached in a key clinical trial designed to evaluate anti-tumor necrosis factor (“TNF”) for patients with early-stage, pain predominant frozen shoulder. The company announced that the first patient has been randomized in the trial, which is funded by UK-based National Institute […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Grant Award to the University of Oxford to Conduct Anti-TNF Therapy Trial
July 27, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced that a team led by researchers at University of Oxford were awarded a grant from the National Institute for Health and Care Research (“NIHR”) in the U.K. to conduct a feasibility trial. The trial will investigate whether anti-tumor necrosis factor (“TNF”) therapy, administered at […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Secures $6.5M in Registered Direct Offering
July 21, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced the closing of its registered direct offering to a single health care-focused U.S. institutional investor. The offering consisted of 6,132,076 shares of the company’s common stock (including common stock equivalents in lieu thereof) and warrants to purchase up to 6,132,076 shares of common stock […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $6.5M Registered Direct Offering
July 18, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced its entry into a definitive agreement with a single health care-focused U.S. institutional investor, for the purchase and sale of 6,132,076 shares of the company’s common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 6,132,076 shares of common […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) CEO Issues Letter to Stockholders
June 23, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, has released a letter to stockholders from its Chief Executive Officer Dr. James Woody. In the letter, Dr. Woody provides an update on the company’s plans for developing a novel therapy for patients with early-stage Dupuytren’s disease, “Our overall aim continues to be to develop new, […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Shares Status of Anti-TNF Treatment, Responses from MHRA and FDA
June 15, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has shared progress status on the company’s anti-TNF treatment, adalimumab, designed to treat early-stage Dupuytren’s disease. The company has reached out to the U.K. Medicines and Healthcare products Regulatory Agency […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Initiates Formal Discussions with UK and US Regulatory Authorities Following Promising Dupuytren’s Trial
May 31, 2022
180 Life Sciences (NASDAQ: ATNF) is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain. The company today announced that, following publication of promising data from a phase 2b Dupuytren’s trial in the June 2022 issues of The Lancet Rheumatology, 180 Life Sciences […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Report Positive Results of Dupuytren’s Disease Study
May 2, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has published the final results of its phase 2b study of patients with Dupuytren’s disease. The results were published in “The Lancet Rheumatology.” According to the announcement, highlights of the report […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Scientific Advisory Board
February 17, 2022
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has formed a scientific advisory board (“SAB”). Initial board members include the following: Dr. Raphael Mechoulam from the Hebrew University in Israel; Dr. Kevin Tracey from Hofstra/Horthwell in the United States; […]